Skip to main content
. 2018 Feb 9;14:1744806918761238. doi: 10.1177/1744806918761238

Figure 2.

Figure 2.

Intrathecal (i.t.) pre-treatment with BmK AGAP (5 µg) inhibited CCI-induced spinal Fos protein expression, accompanied by decreased expression of spinal p-MAPKs. (a) Schematic illustration of the experimental protocol. (b) The representative immunohistochemical staining and quantitative data demonstrating decreased CCI-induced spinal Fos expression by pre-treatment with BmK AGAP. **P < 0.01 compared with saline (Sal)+CCI group; n = 4 mice in each group; scale bar = 200 µm. (c) The representative bands and the quantitative data for demonstrating modulation of spinal p38, p-ERK, and p-JNK expression induced by CCI after pre-treatment with BmK AGAP. The fold-change in the density of each p-MAPK band was normalized to the total MAPK expression for each sample. The fold-change in p-MAPK levels in the Sal + Sham group was set at 1 for quantification. **P < 0.01 or *P < 0.05 compared with Sal + CCI group, ##P < 0.01 compared with Sal + Sham group, n = 4 mice in each group. CCI: chronic constrictive injury; p-MAPK: Phosphorylated mitogen-activated protein kinase; p-ERK: phosphorylated extracellular signal–regulated protein kinase; p-JNK: phosphorylated Jun N-terminal kinase.